Journal List > J Rheum Dis > v.25(4) > 1102070

Lee and Song: Association between Circulating Adiponectin Levels and Osteoarthritis: A Meta-analysis

Abstract

Objective

The aim of this study was to analyze the relationship between the circulating adiponectin levels and osteoarthritis (OA).

Methods

Meta-analysis was conducted on the serum/plasma adiponectin levels in patients with OA and controls, and subgroup analysis was performed based on ethnicity, sex, OA site, and adjustment for age, sex, and/or body mass index (BMI).

Results

Seven studies with eleven comparisons including 538 patients with OA and 366 controls were selected, which showed that the adiponectin levels were significantly higher in the OA group than in controls (standardized mean difference [SMD]=0.745, 95% confidence interval [CI]=0.316∼1.174, p=0.001). Stratification according to ethnicity showed significantly elevated adiponectin levels in Caucasian individuals with OA (SMD=0.769, 95% CI=0.218∼1.319, p=0.006). Stratification according to sex revealed significantly higher adiponectin levels in women with OA, but not in men (SMD=0.861, 95% CI=0.099∼1.623, p=0.027; SMD=1.177, 95% CI=−0.911∼3.316, p=0.281). Stratification by an adjustment for age, sex, or BMI showed significantly higher adiponectin levels in the OA group (SMD=0.837, 95% CI=0.326∼1.349, p=0.001). Stratification according to the OA site showed significantly higher adiponectin levels in patients with knee OA (SMD=0.938, 95% CI=0.456∼1.419, p<0.001).

Conclusion

The significantly higher levels of circulating adiponectin in patients with OA than in healthy controls indicates that adiponectin likely plays a role in the pathogenesis of OA.

REFERENCES

1. Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, Klag MJ. Body mass index in young men and the risk of subsequent knee and hip osteoarthritis. Am J Med. 1999; 107:542–8.
2. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013; 21:16–21.
crossref
3. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013; 9:191–200.
4. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens). 2012; 11:8–20.
crossref
5. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces proinflammatory programs in human macrophages and CD4+ T cells. J Biol Chem. 2012; 287:36896–904.
crossref
6. Lee YA, Ji HI, Lee SH, Hong SJ, Yang HI, Chul Yoo M, et al. The role of adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial cells and osteoblasts: implications for arthritic joints. Exp Mol Med. 2014; 46:e72.
crossref
7. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112:91–100.
crossref
8. Toussirot E, Michel F, Béreau M, Dehecq B, Gaugler B, Wendling D, et al. Serum adipokines, adipose tissue measurements and metabolic parameters in patients with advanced radiographic knee osteoarthritis. Clin Rheumatol. 2017; 36:2531–9.
crossref
9. Tootsi K, Kals J, Zilmer M, Paapstel K, Märtson A. Severity of osteoarthritis is associated with increased arterial stiffness. Int J Rheumatol. 2016; 2016; 6402963.
crossref
10. Honsawek S, Chayanupatkul M. Correlation of plasma and synovial fluid adiponectin with knee osteoarthritis severity. Arch Med Res. 2010; 41:593–8.
crossref
11. Cuzdan Coskun N, Ay S, Evcik FD, Oztuna D. Adiponectin: is it a biomarker for assessing the disease severity in knee osteoarthritis patients? Int J Rheum Dis. 2017; 20:1942–9.
crossref
12. Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls. J Rheumatol. 2009; 36:1885–91.
crossref
13. Filková M, Lisková M, Hulejová H, Haluzík M, Gatterová J, Pavelková A, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis. 2009; 68:295–6.
14. de Boer TN, van Spil WE, Huisman AM, Polak AA, Bijlsma JW, Lafeber FP, et al. Serum adipokines in osteoarthritis; comparison with controls and relationship with local parameters of synovial inflammation and cartilage damage. Osteoarthritis Cartilage. 2012; 20:846–53.
crossref
15. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6:e1000097.
crossref
16. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13.
crossref
17. Wells GA, Shea B, O'connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa (ON): The Ottawa Hospital Research Institute;2000. Available from:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
18. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed.New York: Psychology Press;2009.
19. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997; 315:1533–7.
crossref
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–88.
crossref
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21:1539–58.
crossref
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34.
crossref
23. Duval S, Tweedie R. Trim and fill: A simple fun-nel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56:455–63.
crossref
24. Koskinen A, Juslin S, Nieminen R, Moilanen T, Vuolteenaho K, Moilanen E. Adiponectin associates with markers of cartilage degradation in osteoarthritis and induces production of proinflammatory and catabolic factors through mitogen-activated protein kinase pathways. Arthritis Res Ther. 2011; 13:R184.
crossref
25. Chen TH, Chen L, Hsieh MS, Chang CP, Chou DT, Tsai SH. Evidence for a protective role for adiponectin in osteoarthritis. Biochim Biophys Acta. 2006; 1762; 711–8.
crossref
26. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004; 323:630–5.
crossref
27. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology. 2007; 148:5478–86.

Figure 2.
Meta-analysis of the relationship between adiponectin levels and osteoarthritis (OA). Std diff: standard difference, CI: confidence interval.
jrd-25-231f1.tif
Figure 1.
Flow diagram of the study selection process. OA: osteoarthritis.
jrd-25-231f2.tif
Figure 3.
Funnel plot of studies that examined the association between adiponectin levels and osteoarthritis (Egger's regression p-value=0.559). The filled circles represent studies that showed publication bias. The diamonds at the bottom of the figure show summary effect estimates before (open) and after (filled) publication bias adjustment. Std diff: standard difference, Std err: standard error.
jrd-25-231f3.tif
Table 1.
Characteristics of individual studies included in the meta-analysis
Author Country Ethnicity Patient Age (yr) Sex (female/male) BMI OA site Matched Quality score
OA Control OA Control OA Control OA Control
Toussirot-1, 2017 [8] France European 23 22 64.5±0.2* 59.7±0.1* 23/0 22/0 29.9±0.9* 24.9±0.7* Knee Sex 7
Toussirot-2, 2017 [8] France European 27 28 64.5±0.2* 59.7±0.1* 0/27 0/28 29.9±0.9* 24.9±0.7* Knee Sex 7
Tootsi, 2016 [9] Estonia European 70 70 62.0±7.0 60.0±7.0 35/35 34/36 28.0±3.0 26.0±3.0 Knee, hip Age, sex 7
Cuzdan-1, 2015 [11] Turkey Turkish 30 25 6 67.03±12.71 43.08±14.60 27/3 13/12 23.39±1.77 27.45±5.55 Knee NA 6
Cuzdan-2, 2015 [11] Turkey Turkish 30 25 6 64.56±10.60 43.08±14.60 30/0 98/34 33.11±3.42 27.45±5.55 Knee NA 6
de Boer, 2012 [14] Netherlands European 172 132 67.4±8.4 56.5±4.5 119/53 19/5 29.5±5.3 28.1±3.8 Knee Sex 7
Honsawek, 2010 [10] Thailand Asian 76 24 69.8±1.1* 71.2±1.5* 62/14 26/0 26.1±0.6* 25.5±0.6* Knee, hip Age, sex, BMI 8
Laurberg-1, 2009 [12] Denmark European 22 26 63.0±10.3 46.0±14.4 22/0 0/19 29.9±5.2 NA Knee Sex 7
Laurberg-2, 2009 [12] Denmark European 13 19 65.0±7.8 54.0±7.4 0/13 20/0 27.1±4.0 NA Knee Sex 7
Filkova-1, 2009 [13] Czech European 27 20 NA NA 27/0 20/0 NA NA Knee, hip Sex 6
Filkova-2, 2009 [13] Czech European 48 20 NA NA 48/0 20/0 NA NA Knee, hip Sex 6

Values are presented as number only or mean±standard deviation. OA: osteoarthritis, BMI: body mass index, NA: not available.

* Standard error.

Table 2.
Meta-analysis of adiponectin levels in patients with OA compared to that in controls
Group Population Study (n) Number Test of association Test of heterogeneity
OA Control SMD* 95% CI p-value Model p-value I2
All Overall 11 538 366 0.745 0.316∼1.174 0.001 R <0.001 88.4
Ethnicity European 8 402 337 0.769 0.218∼1.319 0.006 R <0.001 90.6
  Turkish 2 60 25 0.362 −0.017∼0.741 0061 F 0.274 16.2
  Asian 1 76 24 1.377 0.880∼1.874 <0.001 NA NA NA
Sex Female 4 20 68 0.861 0.099∼1.623 0.027 R <0.001 84.4
  Male 2 40 47 1.177 −0.911∼3.316 0.281 R <0.001 94.0
Age-, sex-, or BMI-matched Matched 9 478 341 0.837 0.326∼1.349 0.001 R <0.001 90.3
  Not-matched 2 60 25 0.362 −0.017∼0.741 0.061 F 0.274 16.2
OA site Knee 7 317 252 0.938 0.456∼1.419 <0.001 R <0.001 83.3
  Knee, hip 4 221 114 0.409 −0.377∼1.194 0.308 R < 0.001 90.9

OA: osteoarthritis, SMD: standard mean difference, CI: confidence interval, BMI: body mass index, F: fixed effects model, R: random effects model, NA: not available. *Magnitude of Cohen's d effect size (SMD): 0.2∼0.5, small effect; 0.5∼0.8, medium effect; ≥0.8, large effect.

TOOLS
Similar articles